Randomized Phase II Study of Duligotuzumab (MEHD7945A) versus Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEGHAN Study)
Background: Duligotuzumab, a novel dual-action humanized IgG1 antibody that blocks ligand binding to EGFR and HER3, inhibits signaling from all ligand-dependent HER dimers, and can elicit antibody dependent cell mediated cytotoxicity. High tumor-expression of neuregulin 1 (NRG1), a ligand to HER3, m...
Main Authors: | Jérôme FAYETTE, Lori Wirth, Cristina Oprean, Anghel Udrea, Antonio Jimeno, Danny Rischin, Christopher Nutting, Paul M. Harari, Tibor Csoszi, Dana Cernea, Paul O’Brien, William D. Hanley, Amy V. Kapp, Maria Anderson, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Jan Baptist Vermorken |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2016-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00232/full |
Similar Items
-
Etude de l'impact du vieillissement sur les effets métaboliques et musculaires de la Neureguline 1
by: Caillaud, Kevin
Published: (2015) -
High Levels of Low-Density Lipoproteins Correlate with Improved Survival in Patients with Squamous Cell Carcinoma of the Head and Neck
by: Torben Wilms, et al.
Published: (2021-05-01) -
MEHD is back
Published: (2011-06-01) -
Association between novel <it>PLCE1 </it>variants identified in published esophageal cancer genome-wide association studies and risk of squamous cell carcinoma of the head and neck
by: Liu Zhensheng, et al.
Published: (2011-06-01) -
Transfer-RNA-Derived Fragments Are Potential Prognostic Factors in Patients with Squamous Cell Carcinoma of the Head and Neck
by: Xiaolian Gu, et al.
Published: (2020-11-01)